Development and validation of HPLC method for simultaneous estimation of erlotinib and niclosamide from liposomes optimized by screening design

References

• Abbasi, H., et al., 2022. Functionalized liposomes as drug nanocarriers for active targeted cancer therapy: a systematic review. Journal of liposome research, 32 (2), 195–210.
   PubMed Web of Science ®Google Scholar
• Abdelgalil, A.A., Al-Kahtani, H.M., and Al-Jenoobi, F.I., 2020. Erlotinib, profiles of drug substances. Excipients and related methodology, 45, 93–117.
   PubMedGoogle Scholar
• Ahmed, K.S., et al., 2020. Liposome-based codelivery of celecoxib and doxorubicin hydrochloride as a synergistic dual-drug delivery system for enhancing the anticancer effect. Journal of liposome research, 30 (3), 285–296..
   PubMed Web of Science ®Google Scholar
• Ahmed, T.A., 2015. Preparation of transfersomes encapsulating sildenafil aimed for transdermal drug delivery: Plackett–Burman design and characterization. Journal of liposome research, 25 (1), 1–10.
   PubMed Web of Science ®Google Scholar
• Al-Hadiya, B.M.H., 2005. Niclosamide: comprehensive profile. Profiles of drug substances, excipients, and related methodology, 32 (05), 67–96.
   PubMedGoogle Scholar
• Bhattacharyya, S., Adhikari, H., and Regmi, D., 2019. A brief review on qbd approach on liposome and the requirements for regulatory approval. Research journal of pharmacy and technology, 12 (8), 4057–4065.
   Google Scholar
• Bluthgen, M.V., and Besse, B., 2015. Second-line combination therapies in nonsmall cell lung cancer without known driver mutations. European respiratory review : an official journal of the european respiratory society, 24 (138), 582–593.
   PubMedGoogle Scholar
• Borman, P., and Elder, D., 2017. Q2 (R1) validation of analytical procedures. ICH Quality guidelines, 5, 127–166.
   Google Scholar
• Chen, W., et al., 2018. Niclosamide: beyond an antihelminthic drug. Cellular signalling, 41, 89–96.
   PubMed Web of Science ®Google Scholar
• Danaei, M., et al., 2018. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics, 10 (2), 17–57.
   PubMed Web of Science ®Google Scholar
• Das, A., et al., 2019. Physicochemical characterization of dual action liposomal formulations: anticancer and antimicrobial. Heliyon, 5 (8), e02372.
   PubMed Web of Science ®Google Scholar
• Franken, L.E., Boekema, E.J., and Stuart, M.C.A., 2017. Transmission electron microscopy as a tool for the characterization of soft materials: application and interpretation. Advanced Science, 4 (5), 1600476–1600479.
   Web of Science ®Google Scholar
• Gupta, U., et al., 2014. Spectroscopic studies of cholesterol: fourier transform infra-red and vibrational frequency analysis. Materials focus, 3 (3), 211–217.
   Google Scholar
• Jain, A., Hurkat, P., and Jain, S.K., 2019. Development of liposomes using formulation by design: Basics to recent advances. Chemistry and physics of lipids, 224, 104764.
   PubMed Web of Science ®Google Scholar
• Jannu, A.K., et al., 2021. Lithocholic acid-tryptophan conjugate (UniPR126) based mixed micelle as a nano carrier for specific delivery of niclosamide to prostate cancer via EphA2 receptor. International journal of pharmaceutics, 605, 120819.
   PubMed Web of Science ®Google Scholar
• Kadri, H., Lambourne, O.A., and Mehellou, Y., 2018. Niclosamide, a drug with many (re)purposes. ChemMedChem, 13 (11), 1088–1091.
   PubMed Web of Science ®Google Scholar
• Kesharwani, P., et al., 2021. Qbd enabled azacitidine loaded liposomal nanoformulation and its in vitro evaluation. Polymers, 13 (2), 250–18.
   PubMed Web of Science ®Google Scholar
• Kuligowski, J., et al., 2008. On-line gel permeation chromatography-attenuated total reflectance-Fourier transform infrared determination of lecithin and soybean oil in dietary supplements. Journal of chromatography. A, 1185 (1), 71–77.
   PubMed Web of Science ®Google Scholar
• Kurmi, B.D., and Paliwal, S.R., 2022. Development and optimization of TPGS-based stealth liposome of doxorubicin using Box–Behnken design: characterization, hemocompatibility, and cytotoxicity evaluation in breast cancer cells. Journal of liposome research, 32 (2), 129–145.
   PubMed Web of Science ®Google Scholar
• Latha, S.T., et al., 2017. Development and validation of RP-HPLC method for the estimation of Erlotinib in pharmaceutical formulation. Arabian journal of chemistry, 10, S1138–S1144.
   Web of Science ®Google Scholar
• Li  , et al., 2014. Multi-targeted therapy of cancer by niclosamide: a new application for an old drug. Cancer Letter, 23 (1), 1–7.
   Google Scholar
• Li, R., You, S., et al., 2013. Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer. PLoS One, 8 (9), e74670–13.
   PubMed Web of Science ®Google Scholar
• Li, R., Hu, Z., et al., 2013. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Molecular cancer therapeutics, 12 (10), 2200–2212.
   PubMed Web of Science ®Google Scholar
• Loukas, Y.L., 2001. A Plackett–Burnam screening design directs the efficient formulation of multicomponent DRV liposomes. Journal of pharmaceutical and biomedical analysis, 26 (2), 255–263.
   PubMed Web of Science ®Google Scholar
• Maeda, H., and Khatami, M., 2018. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor‐selective drug delivery, low therapeutic efficacy and unsustainable costs. Clinical and translational medicine, 7 (1), 1–20.
   PubMedGoogle Scholar
• Mamot, C., et al., 2003. Liposome-based approaches to overcome anticancer drug resistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 6 (5), 271–279.
   PubMed Web of Science ®Google Scholar
• Mansoori, B., et al., 2017. The different mechanisms of cancer drug resistance: A brief review. Advanced pharmaceutical bulletin, 7 (3), 339–348.
   PubMed Web of Science ®Google Scholar
• Mokhtari, R.B., et al., 2017. Combination therapy in combating cancer. Oncotarget, 8 (23), 38022–38043.
   PubMedGoogle Scholar
• Nguyen, K.-S.H., Kobayashi, S., and Costa, D.B., 2009. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clinical lung cancer, 10 (4), 281–289..
   PubMed Web of Science ®Google Scholar
• Paghadar, C., and Vadia, N.H., 2019. Development and validation of stability indicating RP-HPLC and HPTLC for determination of niclosamide in bulk and in synthetic mixture. Arabian journal of chemistry, 12 (8), 1803–1814.
   Web of Science ®Google Scholar
• Pezeshky, A., et al., 2016. Vitamin A palmitate-bearing nanoliposomes: Preparation and characterization. Food bioscience, 13, 49–55.
   Web of Science ®Google Scholar
• Plana, D., Palmer, A.C., and Sorger, P.K., 2022. Independent Drug Action in Combination Therapy: Implications for Precision Oncology. Cancer discovery, 12 (3), 606–624.
   PubMed Web of Science ®Google Scholar
• Rahman, Z., et al., 2010. Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design. International journal of pharmaceutics, 389 (1-2), 186–194.
   PubMed Web of Science ®Google Scholar
• Ramani, V.D., Jani, G.K., and Sailor, G.U., 2021. Application of Plackett-Burman design for screening of factors affecting pitavastatin nanoparticle formulation development. Folia medica, 63 (5), 775–785.
   PubMedGoogle Scholar
• Ricciardi, S., Tomao, S., and de Marinis, F., 2011. Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer. Lung cancer 2, 1–9.
   PubMedGoogle Scholar
• Rudin, C.M., et al., 2008. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. Journal of clinical oncology : official journal of the American society of clinical oncology, 26 (7), 1119–1127.
   PubMed Web of Science ®Google Scholar
• Sahu, A.K., and Jain, V., 2017. Screening of process variables using Plackett–Burman design in the fabrication of gedunin-loaded liposomes. Artificial cells, nanomedicine, and biotechnology, 45 (5), 1011–1022.
   PubMed Web of Science ®Google Scholar
• Sangshetti, J.N., et al., 2017. Quality by design approach: regulatory need. Arabian journal of chemistry, 10, S3412–S3425.
   Web of Science ®Google Scholar
• Sarfraz, M., et al., 2018. Development of dual drug loaded nanosized liposomal formulation by a reengineered ethanolic injection method and its pre-clinical pharmacokinetic studies. Pharmaceutics, 10 (3), 151–22.
   PubMed Web of Science ®Google Scholar
• Shi, L., et al., 2017. Niclosamide inhibition of STAT3 synergizes with erlotinib in human colon cancer. OncoTargets and therapy, 10, 1767–1776.
   PubMed Web of Science ®Google Scholar
• Skoczen, S.L., and Stern, S.T., 2018. Improved ultrafiltration method to measure drug release from nanomedicines utilizing a stable isotope tracer. Methods in molecular biology, 1682, 223–239.
   PubMedGoogle Scholar
• Smith, M.C., et al., 2017. Zeta potential: a case study of cationic, anionic, and neutral liposomes. Analytical and bioanalytical chemistry, 409 (24), 5779–5787.
   PubMed Web of Science ®Google Scholar
• Solomon, D., et al., 2017. Role of in vitro release methods in liposomal formulation development: challenges and regulatory perspective. The AAPS journal, 19 (6), 1669–1681.
   PubMed Web of Science ®Google Scholar
• Rojanasathit, S., and Haddad, J. G., 1976. Hepatic accumulation of vitamin D3 and 25-hydroxyvitamin D3. Biochimica et Biophysica Acta (BBA) - General Subjects, 421(1), 12–21.
   Google Scholar
• Song, Z., et al., 2021. Improving breviscapine oral bioavailability by preparing nanosuspensions, liposomes and phospholipid complexes. Pharmaceutics, 13 (2), 132–20.
   PubMed Web of Science ®Google Scholar
• Sun, W., et al., 2016. Drug combination therapy increases successful drug repositioning. Drug discovery today, 21 (7), 1189–1195.
   Google Scholar
• Sung, H., et al., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71 (3), 209–249.
   PubMed Web of Science ®Google Scholar
• Tang, J., et al., 2013. Erlotinib resistance in lung cancer: current progress and future perspectives. Frontiers in pharmacology, 4, 15–19.
   PubMed Web of Science ®Google Scholar
• Vanaja, K., and Rani, R.H.S., 2007. Design of experiments: concept and applications of plackett burman design. Clinical research and regulatory affairs, 24 (1), 1–23.
   Google Scholar
• Wang, X., et al., 2019. Drug resistance and combating drug resistance in cancer. Cancer drug resistance, 2 (2), 141–160.
   PubMedGoogle Scholar
• Wang, H., and Huang, Y., 2020. Combination therapy based on nano codelivery for overcoming cancer drug resistance. Medicine in drug discovery, 6 (3), 100024.
   Google Scholar